BOSTON, Aug. 3, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq:NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that it has received the first site Institutional Review Board (IRB) approval for Zeid Kayali, M.D., Medical Director at Inland Empire Liver Foundation, in Rialto, CA, to proceed with the Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, for the treatment of nonalcoholic steatohepatitis (NASH). The dosing of the first patient in part one of the two-part, Phase 2a clinical trial of DA-1241 is expected to occur in September of 2023.
Read more at prnewswire.comNeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
PR Newswire - Thu Aug 3, 2023 Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Jen-Hsun%20Huan%20NVIDIA's%20Founder%2C%20President%20and%20CEO%20by%20jamesonwu1972%20via%20Shutterstock.jpg)
